Important Safety Information
Clomiphene citrate is classified as Pregnancy Category X and is contraindicated in pregnant women. It should not be used in patients with hypersensitivity to clomiphene, hepatic impairment, abnormal uterine bleeding, uncontrolled thyroid or adrenal dysfunction, or a history of ovarian cysts not related to polycystic ovary syndrome.
Visual symptoms have been reported with clomiphene use, including blurred vision, floaters, photophobia, and scotomata. Patients experiencing any visual disturbance should discontinue treatment and undergo prompt ophthalmological evaluation.
Important
Non-Medical Use
Non-medical use of clomiphene falls outside approved indications. Product purity does not establish that non-medical use is safe or appropriate for an individual. Clomiphene should be used under medical supervision.
Potential Adverse Effects
Common adverse reactions (incidence ≥1%) include ovarian enlargement (13.6%), vasomotor flushes (10.4%), abdominal-pelvic discomfort (5.5%), nausea and vomiting (2.2%), breast discomfort (2.1%), and visual complaints including blurred vision, floaters, and photophobia.
Serious adverse events reported post-marketing include deep vein thrombosis, pulmonary embolism, pancreatitis, hepatic transaminase elevation, and psychiatric symptoms including anxiety, irritability, and psychosis. Ovarian hyperstimulation syndrome (OHSS) has been reported and can progress rapidly within 24 hours.
Prolonged clomiphene use may elevate serum desmosterol levels due to interference with cholesterol synthesis, though sterol levels are not significantly altered at recommended doses.
Conditions Requiring Medical Evaluation
Clomiphene is not appropriate for everyone. Contraindications include pregnancy, breastfeeding, history of hepatic impairment, abnormal uterine bleeding, uncontrolled adrenal dysfunction, non-PCOS-related ovarian cysts, organic intracranial lesions, uncontrolled thyroid disease, pituitary tumor, and endometrial cancer.
Caution is advised in patients with a history of thrombophlebitis or thromboembolic events, as case reports describe deep vein thrombosis following clomiphene treatment. Fasting lipid panel monitoring is recommended for patients at risk of hypertriglyceridemia.
Monitoring During Therapy
Medically supervised clomiphene therapy may involve pregnancy testing and pelvic examination before each treatment cycle. In male hypogonadism research, serum testosterone, LH, and FSH levels are typically monitored to assess response and guide dosing. Any visual symptoms warrant immediate discontinuation and ophthalmological evaluation.
Product Care
Storage & Handling
Store tablets in a cool, dry place in the original packaging. Keep out of reach of children. Inspect tablets before use and do not use if they appear damaged or compromised.
Further Safety Information